Short-term hormone therapy added to radiation increases survival for medium-risk, but not low-risk, prostate cancer patients
Short-term hormone therapy given prior to and during radiation treatment to medium-risk prostate cancer patients increases their chance of living longer, compared to those who receive radiation alone, however there is no significant benefit for low-risk patients, according to the largest randomized study of its kind presented at the plenary session November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO). This phase III study is one of the largest clinical trials of prostate cancer therapy ever completed, with 2,000 low- and intermediate-risk patients enrolled in the trial from October 1994 to April 2001. Researchers from the Radiation Therapy Oncology Group (RTOG) followed men with early-stage prostate cancer for a period in most cases of more than nine years. This timeframe was sufficient to show improved survival benefits of short-term hormone therapy added to what was then the standard radiation treatment for prostate cancer, which involved slightly lower doses of radiation than are currently used today with newer techniques, such as intensity modulated radiation therapy (IMRT).
"The study provides strong scientific evidence that shows us when to deliver hormone therapy with radiation in patients with localized prostate cancer," Christopher U. Jones, M.D., an author of the study and a radiation oncologist at Radiological Associates of Sacramento in Sacramento, Calif., said. "Our findings show that men with low-risk disease, which is the vast majority of prostate cancer patients, have little to gain from adding hormone therapy to radiation. However, men with intermediate-risk disease, which is a significant minority of patients, gain a benefit in overall survival from the addition of only four months of hormone therapy. Prior to this trial, it was unclear whether or not combining hormone therapy with radiation for medium-risk prostate cancer patients improves survival."
Androgen deprivation therapy is hormone therapy used to treat prostate cancer by stopping or lowering the level of male hormones, or androgens, thereby removing the strongest growth factor for prostate cancer cells.
In the study, a total of 1,979 eligible men who had cancer confined to the prostate and a PSA less than or equal to 20 were randomized to receive total androgen deprivation therapy two months prior to and two months during radiation treatment, or radiation alone.
Findings show that short-term hormone therapy given to early-stage prostate cancer patients prior to and during radiation treatment significantly increases their chance of living longer (51 percent), compared to those who receive radiation alone (46 percent). Nearly all of the survival benefit was in the intermediate-risk group. Secondary endpoints of disease-free survial, freedom from biochemical failure, and positive two year re-biopsy rates were also better in the group who received short-term hormone therapy and radiation treatment.
Source: American Society for Radiation Oncology
Articles on the same topic
- Time between treatment and PSA recurrence predicts death from prostate cancerWed, 4 Nov 2009, 20:09:57 UTC
- Radiation therapy after lumpectomy for breast cancer can be safely reduced to 4 weeksWed, 4 Nov 2009, 18:11:33 UTC
- 3-week course of breast radiation may be as effective as conventional 5- to 7-week course for early breast cancersWed, 4 Nov 2009, 18:11:32 UTC
- Does race, income predict prostate cancer outcome?Wed, 4 Nov 2009, 17:31:18 UTC
- Cancer patients want honesty, compassion from their oncologistWed, 4 Nov 2009, 17:31:15 UTC
- Shorter radiation course stops cancer growth in high-risk prostate cancer patientsTue, 3 Nov 2009, 18:26:31 UTC
- Shorter radiation course as effective as standard therapy for prostate cancer recurrenceTue, 3 Nov 2009, 18:26:29 UTC
- Radiation therapy technique successfully treats pain in patients with advanced cancerTue, 3 Nov 2009, 16:08:59 UTC
- PET imaging before radiation not ideal for determining boost radiation dosesTue, 3 Nov 2009, 15:46:33 UTC
- Obesity significantly increases side effects of stereotactic body radiation therapy in lung cancer patientsMon, 2 Nov 2009, 18:24:29 UTC
- Proton therapy is well-tolerated in prostate cancer patientsMon, 2 Nov 2009, 17:59:49 UTC
- Stereotactic radiotherapy stops lung cancer from growing in frail patientsMon, 2 Nov 2009, 17:44:13 UTC
- Stereotactic radiotherapy stops lung cancer from growing in frail patientsMon, 2 Nov 2009, 17:44:11 UTC
- Stereotactic radiotherapy offers noninvasive, effective treatment for lung cancer patientsMon, 2 Nov 2009, 17:44:10 UTC
- Adding proton therapy 'boost' to X-ray radiation therapy reduces prostate cancer recurrencesMon, 2 Nov 2009, 17:39:33 UTC
- Short-term hormone therapy and intermediate dose radiation increases survivial for early stage prostate cancerMon, 2 Nov 2009, 17:15:37 UTC
- Preventative brain radiation for lung cancer patients: Benefits and risksMon, 2 Nov 2009, 16:51:41 UTC
- Undetectable PSA after radiation is possible and predicts good patient outcomesMon, 2 Nov 2009, 16:33:07 UTC
- Additional, specialized radiation not necessary for some women after mastectomyMon, 2 Nov 2009, 16:33:05 UTC
- Real benefits vs. risks of preventative brain radiation for nonsmall cell lung cancer patientsMon, 2 Nov 2009, 16:33:04 UTC
- Radiation after surgery reduces chance of melanoma returningMon, 2 Nov 2009, 16:33:03 UTC
Other sources
- Irradiated cancers stay downfrom Science AlertThu, 5 Nov 2009, 8:14:23 UTC
- Radiation therapy after lumpectomy for breast cancer can be safely reduced to 4 weeksfrom PhysorgWed, 4 Nov 2009, 21:28:05 UTC
- Cancer patients want honesty, compassion from their oncologistfrom PhysorgWed, 4 Nov 2009, 19:14:06 UTC
- Radiation therapy technique successfully treats pain in patients with advanced cancerfrom Science BlogTue, 3 Nov 2009, 21:07:19 UTC
- PET imaging before radiation not ideal for determining boost radiation dosesfrom PhysorgTue, 3 Nov 2009, 19:56:11 UTC
- Radiation Therapy Technique Successfully Treats Pain In Patients With Advanced Cancerfrom Science DailyTue, 3 Nov 2009, 17:21:13 UTC
- Radiation therapy technique successfully treats pain in patients with advanced cancerfrom PhysorgTue, 3 Nov 2009, 16:35:53 UTC
- Additional, specialized radiation not necessary for some women after mastectomyfrom PhysorgTue, 3 Nov 2009, 7:56:07 UTC
- Adding proton therapy 'boost' to X-ray radiation therapy reduces prostate cancer recurrencesfrom PhysorgTue, 3 Nov 2009, 4:56:07 UTC
- Proton Therapy Is Well-tolerated In Prostate Cancer Patientsfrom Science DailyTue, 3 Nov 2009, 4:14:07 UTC
- Stereotactic radiotherapy stops lung cancer from growing in frail patientsfrom PhysorgTue, 3 Nov 2009, 3:28:16 UTC
- Preventative brain radiation for lung cancer patients: Benefits and risksfrom PhysorgTue, 3 Nov 2009, 3:28:14 UTC
- Proton therapy is well-tolerated in prostate cancer patientsfrom PhysorgTue, 3 Nov 2009, 1:14:18 UTC
- Undetectable PSA after radiation is possible and predicts good patient outcomesfrom PhysorgTue, 3 Nov 2009, 0:07:19 UTC
- Radiation after surgery reduces chance of melanoma returningfrom PhysorgMon, 2 Nov 2009, 22:56:16 UTC
- Obesity significantly increases side effects of stereotactic body radiation therapy in lung cancer patientsfrom PhysorgMon, 2 Nov 2009, 21:49:15 UTC
- Preventative brain radiation for lung cancer patients: Benefits and risksfrom Science BlogMon, 2 Nov 2009, 18:49:09 UTC
- Short-term hormone therapy and intermediate dose radiation increases survivial for early stage prostate cancerfrom PhysorgMon, 2 Nov 2009, 17:42:15 UTC
- Stereotactic Radiotherapy Offers Noninvasive, Effective Treatment for Frail Patients with Early-stage Lung Cancerfrom Newswise - ScinewsMon, 2 Nov 2009, 17:42:07 UTC
- Undetectable PSA After Radiation Is Possible And Predicts Good Patient Outcomesfrom Science DailyMon, 2 Nov 2009, 17:21:30 UTC
- Radiation After Surgery Reduces Chance Of Melanoma Returningfrom Science DailyMon, 2 Nov 2009, 16:28:58 UTC